Evidence map›Paper›PMID 36200921›Full record

ReviewDermatologic therapy2022

Benefits of topical hyaluronic acid for skin quality and signs of skin aging: From literature review to clinical evidence.

Bruna Bravo, Priscila Correia, José Euzébio Gonçalves Junior, Beatriz Sant'Anna, Delphine Kerob

Open access · hybridAbstract readReview
In one paragraph

Review in Dermatologic therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
23.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 126 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Advancements in Functional Polymeric Scaffolds for Scar-Free Skin Regeneration.Polymer science & technology (Washington, D.C.) · 2026
    Review
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Molecules (Basel, Switzerland) · 2026
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Preparation and Investigation ofPharmaceuticals (Basel, Switzerland) · 2026
    Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Bruna BravoBravo's Clinic, Rio de Janeiro, Brazil.ORCID 0000-0001-9692-7967
Priscila CorreiaScientific Expertise, Cosmetic Active, L'Oréal Brasil, Rio de Janeiro, Brazil.ORCID 0000-0001-5099-3678
José Euzébio Gonçalves JuniorScientific Expertise, Cosmetic Active, L'Oréal Brasil, Rio de Janeiro, Brazil.ORCID 0000-0003-3009-4426
Beatriz Sant'AnnaScientific Expertise, Cosmetic Active, L'Oréal Brasil, Rio de Janeiro, Brazil.ORCID 0000-0001-8369-0665
Delphine KerobCosmetic Active International, L'Oréal, Paris, France.ORCID 0000-0003-2816-4261
D’Or Institute for Research and Education · BRL'Oréal (France) · FR

Funding

Cosmetic Active International, L'Oréal
6 · The paper itself

Abstract

Skin aging goes beyond a chronological process and also results from extrinsic factors referred to as the exposome. Hyaluronic acid (HA) is an important component of the extracellular matrix, with loss starting at 25 years old. While many studies of HA concern topical use, few literature reviews only address the use of topical HA in dermatology. This review describes the different characteristics of HA-containing cosmeceuticals, with a focus on skin aging and the impact of exposome factors on HA synthesis and degradation. A review was performed using the terms HA, hyaluronan, topical, dermatology, cosmetic, aging treatment, exposome, and cosmeceuticals. Results are also presented from a recent randomized controlled trial (RCT), which investigated the additional benefit of using a HA epidermic filler (HA-filler serum) combined with Botulinum toxin type A (BoNTA) to treat signs of skin aging. Subjects were randomized to two groups: HA-filler serum starting 24 h after the BoNTA injection then twice daily for 24 weeks, or the control group, which received BoNTA. HA is a key ingredient used in cosmeceuticals for its hydration/antiaging properties (hygroscopic, rheological, and viscoelastic). Several clinical studies indicate that HA is both well tolerated and effective, adjuvant to both post-surgical and facial rejuvenation procedures. In the RCT, one of few studies to combine BoNTA and HA with a 6-month follow-up, the HA-filler serum lengthened the duration of BoNTA's effect in reducing wrinkles. Numerous studies support HA-based cosmeceuticals as a noninvasive, effective solution for improving skin hydration and rejuvenation.

Indexed as

Botulinum Toxins, Type ACosmeceuticalsCosmetic TechniquesDermal FillersSkin AgingAdultHumansHyaluronic AcidRandomized Controlled Trials as TopicRejuvenationBotulinum Toxins, Type ACosmeceuticalsDermal FillersHyaluronic Acidcosmeceuticaldermatologyhyaluronic acidskintopical application

Identifiers

PMID36200921
PMCPMC10078143
OpenAlexW4302762904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.